Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAFV600E Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series

Clin Colorectal Cancer. 2022 Sep;21(3):267-271. doi: 10.1016/j.clcc.2021.12.001. Epub 2021 Dec 31.
No abstract available

Keywords: BRAFV600E; Binimetinib; Cetuximab; Encorafenib; Metastatic colorectal cancer; Rechallenge; Vemurafenib.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Benzimidazoles
  • Carbamates
  • Cetuximab / therapeutic use
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • Humans
  • Mutation
  • Proto-Oncogene Proteins B-raf* / genetics
  • Sulfonamides

Substances

  • Benzimidazoles
  • Carbamates
  • Sulfonamides
  • binimetinib
  • encorafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Cetuximab